brain disease: A disease affecting the brain or part of the brain.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
75 |
4. Check minimum number of eventsNone |
75 |
5. Include endpointsNone |
75 |
6. Filter based on genotype QC (FinnGen only) |
70 |
Control definitions (FinnGen only)
- Control exclude
- G6_OTHNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G93
- Name in latin
- Oedema cerebri
Similar endpoints
↥List of similar endpoints to
Cerebral oedema
based on the number of shared cases.
Similar with more cases:
- Other neurological diseases
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 918 | 430 | 478 |
| Only index persons | 515 | 232 | 283 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 50.49 | 52.34 | 48.62 |
| Only index persons | 51.71 | 52.78 | 50.83 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 70 | 38 | 32 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 56.47 | 55.98 | 57.06 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 75
- Matched controls
- 750
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G93.6
ICD-10 Finland
Cerebral oedema
+∞
102.4
73
*
N03AX14
ATC
levetiracetam; systemic
81.2
27.8
30
6
AA1AD
NOMESCO Finland
CT of head and brain
8.8
20.6
44
104
130
Kela drug reimbursment
Malignant tumour
10.9
19.1
25
33
H02AB02
ATC
dexamethasone; systemic
8.8
18.0
30
53
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
53.5
17.4
20
5
L01AX03
ATC
temozolomide; systemic
+∞
17.3
16
*
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
216.1
17.3
17
*
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
24.8
16.5
23
13
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
7.3
14.8
29
60
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
13.8
14.2
25
26
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
6.3
12.5
28
65
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
56.5
12.4
14
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
6.0
11.1
25
58
N03AX18
ATC
lacosamide; systemic
70.3
11.0
12
*
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
46.8
10.3
12
*
PA2CC
NOMESCO Finland
Cerebral very extensive angiography with X-ray
+∞
8.5
8
*
AAK80
NOMESCO Finland
Partial excision of skull cap
+∞
8.5
8
*
D43.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, supratentorial
+∞
8.5
8
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
20.0
8.4
12
7
R56.8
ICD-10 Finland
Other and unspecified convulsions
10.4
8.3
16
19
WF002
NOMESCO Finland
Radical radiotherapy
10.7
8.0
15
17
TPH04
NOMESCO Finland
Cathetrisation of vein
4.2
7.7
27
88
A03FA01
ATC
metoclopramide; systemic, rectal
4.1
7.5
28
95
C71.23
ICD-10 Finland
Malignant tumor of temporal lobe grade IV glioma
+∞
7.4
7
*
C71.1
ICD-10 Finland
Malignant neoplasm: Frontal lobe
+∞
7.4
7
*
AAK00
NOMESCO Finland
Cranioplasty
+∞
7.4
7
*
AAF00
NOMESCO Finland
Ventriculostomy
+∞
7.4
7
*
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
+∞
7.4
7
*
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
+∞
7.4
7
*
WX882
NOMESCO Finland
High dependency care
14.0
7.4
12
10
R51.80
ICD-10 Finland
Headache
4.3
7.3
24
74
G40.9
ICD-10 Finland
Epilepsy, unspecified
15.8
7.1
11
8
A04AA01
ATC
ondansetron; systemic, rectal
7.3
7.1
17
29
ZXC95
NOMESCO Finland
Use of surgical navigator
44.1
6.9
8
*
WX872
NOMESCO Finland
Intensive care
12.6
6.5
11
10
I69.0
ICD-10 Finland
Sequelae of subarachnoid haemorrhage
76.0
6.5
7
*
A04AA02
ATC
granisetron; systemic, transdermal
7.2
6.4
15
25
C71.2
ICD-10 Finland
Malignant neoplasm: Temporal lobe
+∞
6.3
6
*
C71.10
ICD-10 Finland
Malignant tumor in frontal lobe without histology
+∞
6.3
6
*
N03AF02
ATC
oxcarbazepine; oral
14.2
6.3
10
8
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.8
6.1
17
36
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
30
67
6.80
14.13
16.5
6.1
1.48
1.22
mmol/l
0.16
23
55
9
0
+∞
9.57
1.0
0.0
—
—
—
0
0
11
5
25.34
8.28
1.6
2.2
—
—
—
0
0
14
13
12.92
8.20
2.7
1.5
599.79
402.69
mg/l
0.94
14
13
27
96
3.83
6.72
4.4
2.4
105.00
143.54
ng/l
0.17
21
68
16
41
4.69
6.08
34.2
10.3
24.19
24.90
mmol/l
0.35
16
41
47
251
3.34
6.00
7.9
14.3
1.22
1.25
inr
0.06
11
64
48
261
3.33
5.92
3.2
2.4
—
—
—
0
0
28
119
3.16
5.11
2.9
2.3
—
—
—
0
0
24
93
3.32
5.10
9.2
4.9
0.81
0.82
mmol/l
0.22
24
88
24
93
3.32
5.10
2.9
1.8
—
—
—
0
0
21
82
3.17
4.35
4.0
3.2
3.78
3.24
e6/l
—
10
49
18
65
3.33
4.21
2.7
1.5
—
—
—
0
0
6
5
12.87
3.83
1.2
1.0
—
—
—
0
0
17
65
3.09
3.60
2.6
1.6
—
—
—
0
0
53
359
2.62
3.57
20.3
10.3
3.85
4.13
e9/l
0.44
47
308
6
6
10.72
3.56
4.0
1.0
31.01
17.61
ug/l
—
6
6
48
321
2.38
3.17
13.4
5.9
11.21
11.71
umol/l
0.15
48
303
33
195
2.24
2.84
4.2
3.3
64.03
30.83
u/l
0.84
33
181
10
29
3.82
2.81
2.4
1.5
—
—
—
0
0
5
6
8.81
2.79
1.2
1.0
—
—
—
0
0
5
6
8.81
2.79
1.0
1.0
—
—
—
0
0
12
41
3.29
2.78
22.4
8.0
95.13
92.90
%
0.69
12
41
19
90
2.49
2.67
3.7
2.9
0.88
0.81
e6/l
—
8
55
8
22
3.94
2.44
2.1
2.4
—
—
—
0
0
8
23
3.76
2.34
3.5
2.1
95.13
95.91
%
—
8
23
7
18
4.17
2.31
3.7
2.7
265.43
166.17
%
—
7
18
6
14
4.56
2.19
1.8
1.6
—
—
—
0
0
6
14
4.56
2.19
1.8
1.6
—
—
—
0
0
15
70
2.43
2.16
18.2
6.8
105.87
103.30
mmol/l
1.11
15
70
5
10
5.27
2.10
2.0
2.1
—
—
—
0
0
5
10
5.27
2.10
2.0
2.1
—
—
—
0
0
5
11
4.78
1.97
2.2
1.7
—
—
—
0
0
5
14
3.75
1.64
2.0
1.9
—
—
—
0
0
5
15
3.49
1.55
4.0
1.9
—
—
—
0
0
23
151
1.75
1.33
5.1
3.3
0.21
0.32
e6/l
0.26
13
117
10
49
2.20
1.28
31.7
7.6
1.66
1.05
mmol/l
—
10
42
64
693
0.48
1.24
52.1
19.4
37.35
40.71
%
1.81
55
661
5
19
2.74
1.23
1.0
5.5
26.48
24.47
mmol/l
—
5
19
49
568
0.60
1.18
30.2
12.0
89.52
84.48
ml/min/173m2
0.78
41
455
5
21
2.48
1.11
3.6
2.0
—
—
—
0
0
7
34
2.17
1.06
21.1
7.6
25.29
24.88
mmol/l
—
7
34
7
36
2.04
1.00
1.0
1.3
—
—
—
0
0
0
31
0.00
0.99
0.0
1.8
—
—
—
0
0
6
32
1.95
0.84
2.0
2.3
0.88
1.54
%
—
6
32
29
227
1.45
0.77
3.2
4.0
19.36
36.89
ng/l
1.05
24
156
5
24
2.16
0.76
3.4
2.2
—
—
—
0
0
37
306
1.41
0.72
3.8
3.7
0.00
0.00
estimate
—
5
55
7
42
1.73
0.70
9.3
6.0
77.00
77.74
ng/l
—
7
37
61
653
0.65
0.65
20.6
10.0
38.77
26.51
u/l
1.61
61
636
62
660
0.65
0.60
39.0
14.7
67.37
77.74
umol/l
3.06
62
660
0
23
0.00
0.59
0.0
1.7
—
—
—
0
0
0
23
0.00
0.59
0.0
2.0
—
2.89
—
0
16
25
199
1.38
0.59
5.0
3.5
—
—
—
0
0
5
81
0.59
0.49
2.8
1.5
—
—
—
0
0
5
32
1.60
0.43
62.4
8.5
25.72
24.24
mmol/l
—
5
32
5
33
1.55
0.42
1.0
3.6
5.04
4.63
pmol/l
—
5
28
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
5
35
1.46
0.40
2.2
2.6
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
1.71
—
0
11
5
77
0.62
0.38
3.8
6.4
—
—
—
0
0
5
78
0.62
0.38
2.2
2.1
—
—
—
0
0
6
42
1.47
0.36
2.5
1.7
—
—
—
0
0
40
437
0.82
0.32
3.6
3.3
—
—
—
0
0
7
56
1.28
0.30
4.3
4.5
7.67
9.35
ug/l
—
7
47
63
604
1.27
0.25
37.2
13.4
22.79
22.48
mg/l
0.03
63
462
15
125
1.25
0.25
1.3
1.6
—
—
—
0
0
24
212
1.19
0.23
2.4
1.9
97.23
99.08
pmol/l
0.09
14
106
5
40
1.27
0.23
2.4
2.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
4.5
—
50.17
—
0
11
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
—
—
0
0
23
240
0.94
0.04
4.0
3.9
—
—
—
0
0
45
441
1.05
0.03
3.3
4.1
15.77
14.82
pmol/l
1.11
45
406
53
522
1.05
0.02
47.3
15.7
14.11
14.47
%
0.34
53
514
14
135
1.05
0.00
1.7
1.5
18.83
21.88
nmol/l
0.40
14
114
62
625
0.95
0.00
46.2
14.7
3.97
3.98
mmol/l
0.10
62
612
62
619
1.01
0.00
46.6
14.6
138.63
139.67
mmol/l
1.64
62
607
14
144
0.97
0.00
2.8
4.1
23.51
21.78
%
—
8
60
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
2050.00
—
0
5
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
6.0
—
177.67
—
0
9
Mortality – FinRegistry
↥Association
Association between endpoint G6_CEROEDEMA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_CEROEDEMA | 9.279 [2.77, 31.05] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.032 |
During the follow-up period (1.1.1998 — 31.12.2019), 68 out of 166 females with G6_CEROEDEMA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_CEROEDEMA | 10.985 [5.1, 23.68] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.023 |
During the follow-up period (1.1.1998 — 31.12.2019), 79 out of 184 males with G6_CEROEDEMA died.
Mortality risk
Mortality risk for people of age
years, who have G6_CEROEDEMA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.852% | 1.959% |
| 5 | 4.155% | 10.695% |
| 10 | 11.262% | 27.797% |
| 15 | 21.457% | 48.394% |
| 20 | 33.987% | 69.973% |
Relationships between endpoints
↥Index endpoint: G6_CEROEDEMA – Cerebral oedema
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data